Cargando…

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study

BACKGROUND: The phase 3, prospective PROPEL study demonstrated that pharmacokinetic (PK)-guided prophylaxis targeting elevated factor VIII (FVIII) troughs in patients with hemophilia A resulted in lower annualized bleeding rates (ABRs) and a higher proportion of patients experiencing zero bleeds in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escuriola-Ettingshausen, Carmen, Klamroth, Robert, Escobar, Miguel, Stasyshyn, Oleksandra, Tangada, Srilatha, Engl, Werner, Honauer, Ivan, Lee, Hye-Youn, Chowdary, Pratima, Windyga, Jerzy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350756/ https://www.ncbi.nlm.nih.gov/pubmed/37465396 http://dx.doi.org/10.1177/20406207231178596

Ejemplares similares

Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients
por: You, Chur Woo, et al.
Publicado: (2019)

Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial
por: Gruppo, Ralph, et al.
Publicado: (2019)

A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States
por: Aledort, Louis, et al.
Publicado: (2020)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study
por: Windyga, Jerzy, et al.
Publicado: (2020)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
por: Napolitano, Mariasanta, et al.
Publicado: (2021)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Convenience Comparison Study of Reconstitution Devices for the Blood Coagulation Factor VIII Products Rurioctocog Alfa Pegol and Antihemophilic Factor (Recombinant)
por: Ueda, Hitoshi, et al.
Publicado: (2020)

Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety
por: Stidl, Reinhard, et al.
Publicado: (2018)

Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials
por: Witarto, Bendix Samarta, et al.
Publicado: (2022)

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B
por: Windyga, Jerzy, et al.
Publicado: (2020)

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study
por: Simpson, Mindy L, et al.
Publicado: (2019)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
por: Klamroth, Robert, et al.
Publicado: (2021)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery
por: Pabinger, Ingrid, et al.
Publicado: (2021)

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
por: Dargaud, Yesim, et al.
Publicado: (2021)

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
por: Kearney, Susan, et al.
Publicado: (2019)

Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
por: Lentz, Steven R., et al.
Publicado: (2022)

Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
por: Ettingshausen, Carmen Escuriola, et al.
Publicado: (2023)

Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2016)

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)
por: Auerswald, Guenter, et al.
Publicado: (2020)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)
por: Lissitchkov, Toshko J., et al.
Publicado: (2017)

Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study)
por: Djambas Khayat, Claudia, et al.
Publicado: (2021)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
por: Reding, Mark T., et al.
Publicado: (2023)

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
por: Ay, Cihan, et al.
Publicado: (2022)

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)
por: Lissitchkov, Toshko, et al.
Publicado: (2020)

Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2022)

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials
por: Tosetto, Alberto, et al.
Publicado: (2020)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders
por: Windyga, Jerzy, et al.
Publicado: (2022)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m5mi46l7lndggkao3ubddi7b2a